Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
Giulio Metro(University of Perugia), Paolo Carlini(National Cancer Institute), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanessa Graziano(Tumori Foundation), Alessandra Felici, Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Carmen Nuzzo, G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Domenica Pellegrini(Tumori Foundation), Michelangelo Russillo(National Cancer Institute), Marianna Introna(Tumori Foundation), Paola Papaldo(Cancer Institute (WIA)), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
PubMed
June 5, 2008
Cited by 11
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743